15277 Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials

Abstract

Objective: To summarize the incidence of malignancies by nonmelanoma skin cancer (NMSC) and malignancies other than NMSC or cervical cancer in situ, using pooled data from VOYAGE 1 and 2 through 3 years of guselkumab (GUS) treatment and to compare to expected rates in the general US population.